Prediction of Drug –Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation

ConclusionDabrafenib is a potent noncompetitive inhibitor of UGT1A1 and may bring potential risk of DDI when combined with irinotecan.

Source: European Journal of Drug Metabolism and Pharmacokinetics - February 11, 2022 Category: Drugs & Pharmacology Source Type: research